ArticleJournal of carcinogenesis2013
Nicotine and lung cancer.
Article in Journal of carcinogenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The relation of passive smoking with cervical cancer: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Analyzing large-scale samples confirms the association between the rs1051730 polymorphism and lung cancer susceptibility.Scientific reports · 2015Pooled it
- β-Carotene Supplementation and Lung Cancer Incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: The Role of Tar and Nicotine.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Trial
- No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Cell-specific multi-target mechanisms of cotinine in cervical cancer oncogenesis and progression.Discover oncology · 2026Article
- Predicting Clinical Outcomes and Immunotherapy Responses in Lung Adenocarcinoma Based on Nicotine Response Characteristics.Current medicinal chemistry · 2026Article
- What Is the Evidence for "Resistant Smokers?"American journal of respiratory and critical care medicine · 2025Article
- The prevalence of human papillomavirus and Epstein-Barr virus among laryngoscopy referrals in Northeastern Iran.BMC infectious diseases · 2025Article
- Risk Factors Associated with Urothelial Bladder Cancer.International journal of environmental research and public health · 2024Review
- The Role of Licorice Chalcones as Molecular Genes and Signaling Pathways Modulator-A Review of Experimental Implications for Nicotine-Induced Non-Small Cell Lung Cancer Treatment.Current issues in molecular biology · 2024Review
- Smoking, Lung Cancer Stage, and Prognostic Factors-Findings from the National Lung Screening Trial.International journal of environmental research and public health · 2024Article
- The impact of hormones on lung development and function: an overlooked aspect to consider from early childhood.Frontiers in endocrinology · 2024Review
- Quercetin Derivatives as Potential Therapeutic Agents: An Updated Perspective on the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Review
- Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
- Insights into the Mechanisms of Action of Proanthocyanidins and Anthocyanins in the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer.International journal of molecular sciences · 2022Review
- Tetraspanin CD9: A friend or foe of head and neck cancer (Review).Oncology reports · 2022Review
- Review
- Early effects of cigarette smoke extract on human oral keratinocytes and carcinogenesis in head and neck squamous cell carcinoma.Head & neck · 2020Article
- Reply to Young and Scott: Nicotine and nicotinic acetylcholine receptor mutations in electronic-cigarette smoke lung carcinogenicity.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tobacco use in cancer patients is associated with increased cancer treatment failure and decreased survival. Nicotine is one of over 7,000 compounds in tobacco smoke and nicotine is the principal chemical associated with addiction. The purpose of this article is to review the tumor promoting activities of nicotine. Nicotine and its metabolites can promote tumor growth through increased proliferation, angiogenesis, migration, invasion, epithelial to mesenchymal transition, and stimulation of autocrine loops associated with tumor growth. Furthermore, nicotine can decrease the biologic effectiveness of conventional cancer treatments such as chemotherapy and radiotherapy. Common mechanisms appear to involve activation of nicotinic acetylcholine receptors and beta-adrenergic receptors leading to downstream activation of parallel signal transduction pathways that facilitate tumor progression and resistance to treatment. Data suggest that nicotine may be an important mechanism by which tobacco promotes tumor development, progression, and resistance to cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.